To build upon the clinical benefits of anti-HER2 antibodies and reports of anti-tumor activities of IgEs recognising melanoma and ovarian cancer antigens [18, 19, 24], we sought to generate and evaluate a panel of HER2-targeting IgE antibodies. Here, IGHE is linked to ovarian carcinoma.